Financial Statements

Amicus Therapeutics, Inc. (FOLD)

$12.75

-0.08 (-0.62%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -2,045-1,769-1,412-1,064-
Net Income -250-277-356-349-284
Stock Dividends ---0-780
Dividend Paid -----
Retained Earnings -2,296-2,045-1,769-1,412-1,064

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 6781119-
Annual Depreciation -0-1190914
Capital Expenditure -4-3-20-6-5
Net PPE 636781119

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -198198198198
New Purchases -490-578-384-365-341
Intangible and Goodwill 198198198198198

Amicus Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Amicus Therapeutics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.